Citryll has dosed the first patient in the Phase IIa Citylights clinical trial of the monoclonal antibody, CIT-013, for moderate-to-severe hidradenitis suppurativa (HS), a chronic autoimmune disease.
The placebo-controlled, double-blind, multi-centre, randomised study is assessing two dose levels of CIT-013 in HS patients across North America and Europe.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will evaluate the tolerability, efficacy, and safety in 96 participants over a 12-week period.
In September 2025 , Citryll began a Phase IIa trial of CIT-013 in rheumatoid arthritis (RA).
The antibody targets extracellular traps, implicated in inflammation in HS, RA, and other immune-mediated inflammatory conditions.
It uses a dual mechanism, promoting the removal of existing extracellular traps and preventing the creation of new ones.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCIT-013 reduces off-target effects and represents a potentially new therapeutic approach.
Patients with HS experience pus-draining tunnels and recurring skin lesions, often leading to tissue destruction and scarring.
The company has formed a Clinical Advisory Board for this trial, bringing together international experts in the field.
Citryll chief medical officer Maarten Kraan said: “This is an exciting period for Citryll, initiating this HS trial a few months after starting our Phase IIa trial in rheumatoid arthritis. I’m grateful to our team and clinical partners for their tireless efforts to reach this goal.
“As we advance our investigation of CIT-013 in HS, we look forward to drawing on the expertise of our newly formed clinical advisory board. Underpinning all this work is our desire to deliver a novel, disease modifying therapy for the many HS patients who currently lack suitable treatments.”
In July 2024, Citryll announced the completion of subject dosing in the repeat-dose stage of the Phase I clinical trial of CIT-013.
